

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

PROPOSED ADOPTION OF SHARE SCHEME

The board of directors (the “**Board**”) of Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”) resolved to propose the adoption of a share scheme (the “**Share Scheme**”), with the aim of enabling the Company to provide incentives to eligible participants for their contributions or potential contributions to the Company and/or any of its subsidiaries.

Pursuant to Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), as the Share Scheme involves the grant of new shares and/or options over new shares to or for the benefit of specified participants, as well as the grant of existing shares, the Share Scheme shall comply with the relevant requirements of Chapter 17 of the Listing Rules. The adoption of the Share Scheme is subject to the approval of the shareholders of the Company at a general meeting to be convened in accordance with the articles of association of the Company to consider and, if thought fit, approve the adoption of the Share Scheme, as well as the approval from the Listing Committee of The Stock Exchange of Hong Kong Limited for the listing of, and permission to deal in, any shares that may be allotted and issued in respect of all awarded shares granted under the Share Scheme.

In view of the amendments to Chapter 17 of the Listing Rules, which came into effect on 1 January 2023, the Company intends to replace the existing share award scheme (the “**Existing Share Award Scheme**”) adopted by the Company on 10 February 2022 and the existing share option scheme (together with the Existing Share Award Scheme referred to as the “**Existing Schemes**”) adopted on 18 March 2022 with the Share Scheme. The Existing Schemes will be terminated upon the adoption of the Share Scheme. No awarded shares or share options have been awarded or granted under the Existing Schemes from the date of adoption of the Existing Schemes to the date of this announcement. The Board has no intention of awarding or granting any awarded shares or share options under the Existing Schemes during the period from the date of this announcement to the date of the general meeting of the Company at which the Share Scheme is to be proposed.

A circular containing, amongst other things, further details regarding the proposed adoption of the Share Scheme (including its principal terms), in accordance with the relevant requirements of the articles of association of the Company and the Listing Rules, will be despatched to the shareholders of the Company as soon as practicable.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Dr. Zhaohua Chang
Chairman

Shanghai, China, 14 May 2026

As at the date of this announcement, the executive directors are Dr. Chao He and Mr. Yu Liu, the non-executive directors are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.